Please use this identifier to cite or link to this item:
Title: Pharmacokinetic analysis of pegylated megakaryocyte growth and development factor in humans.
Austin Authors: De Boer, R H;Roskos, L K;Cheung, E ;Fox, S;Basser, R L;Marty, J;Begley, C G;Cebon, Jonathan S 
Affiliation: Ludwig Institute Oncology Unit, Austin Repatriation Medical Centre, Australia
Issue Date: 2000
Publication information: Growth Factors (chur, Switzerland); 18(3): 215-26
Abstract: Phase I studies with pegylated megakaryocyte growth and development factor (PEG-rHuMGDF), a c-Mpl ligand that stimulates megakaryopoiesis, have demonstrated that PEG-rHuMGDF is biologically active alone and causes a dose-related enhancement of platelet recovery when administered after chemotherapy. Here we report the dose-ranging pharmacokinetics of PEG-rHuMGDF. Pre-injection blood samples were drawn daily for pharmacokinetic studies on 43 patients. An ELISA, established using PEG-rHuMGDF as the standard, was able to quantitate Mpl ligand at concentrations > 0.02 ng/mL. Over the dose range 0.03 to 5.0 microg/kg/day, subcutaneous administration produced linear increases in steady-state serum levels. Maximum levels of PEG-rHuMGDF attained after 5.0 microg/kg/day were 5.88 to 10.9 ng/mL. After discontinuation of PEG-rHuMGDF, concentrations of Mpl ligand returned to baseline within 5 days. The pharmacokinetics were best described by a one-compartment model with first-order absorption, an absorption delay, and non linear clearance over the first 48 hours. The mean terminal half-life was 33.3 + 16.7 hours, and the average apparent at steady state was 27.7 + 14.0 mL/h/kg; both were independent of administered dose. The apparent clearance of PEG-rHuMGDF was not predicted by platelet count. Administration of chemotherapy and Filgrastim did not alter the pharmacokinetics of PEG-rHuMGDF.
Gov't Doc #: 11334057
Journal: Growth factors (Chur, Switzerland)
Type: Journal Article
Subjects: Antineoplastic Agents.administration & dosage
Dose-Response Relationship, Drug
Drug Administration Schedule
Enzyme-Linked Immunosorbent Assay.methods
Injections, Subcutaneous
Neoplasms.blood.drug therapy
Platelet Count
Polyethylene Glycols.administration & dosage.pharmacokinetics
Recombinant Proteins.administration & dosage.blood.pharmacokinetics
Thrombopoietin.administration & dosage.blood.pharmacokinetics
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jan 27, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.